Previous 10 | Next 10 |
2024-02-07 01:01:54 ET Summary Rolling NDA submission of avutometinib + defactinib for the treatment of patients with low-grade serous ovarian cancer is expected in the 1st half of 2024, with possible commercialization in 2025. Results from two studies, RAMP-203 and RAMP-204, each...
Expect to Begin Rolling Submission of New Drug Application (NDA) for Accelerated Approval to FDA for Avutometinib and Defactinib Regimen in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) in H1 2024; Prepare for Potential Commercial Launch in 2025 Initial Data Read-Out from RAMP 205 Tri...
2024-01-18 16:28:46 ET More on Verastem Verastem: Potential Accelerated Approval Filing In H1 2024 Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial information for Verastem For further details see: Ve...
Ongoing RAMP 203 Trial Assessing a More Complete Vertical Blockade with RAF/MEK and KRAS G12C Inhibition Along RAS Pathway to Improve Outcomes in KRAS G12C-Mutant NSCLC Confirmed Responses Observed in Both KRAS G12C Inhibitor Naïve and Pre-treated Patients in Initial RAMP 203 Trial R...
2024-01-16 10:52:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Verastem Oncology (Nasdaq: VSTM) (the “Company), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that the Company will participate in a fireside chat at the B. Riley Securities 4 th Annual Oncology Conference on Thursday, Janua...
Investigational New Drug (IND) Submission Planned for GFH375/VS-7375 in H1 2024 No FDA Approved Therapies Available Targeting KRAS G12D, the Most Prevalent KRAS Mutation in Human Cancer Verastem Oncology (Nasdaq: VSTM) (the “Company”), a biopharmaceutical company c...
2023-12-13 12:22:29 ET More on Verastem Verastem: Potential Accelerated Approval Filing In H1 2024 Verastem: Signs Of Life For A Beaten-Down Equity Seeking Alpha’s Quant Rating on Verastem Historical earnings data for Verastem Financial informa...
RAMP 301 Is Evaluating the Combination of Avutometinib and Defactinib vs Investigator’s Choice of Therapy Reported Data from Part A of RAMP 201 Trial Show an Objective Response Rate of 45%, and Manageable Safety and Tolerability Profile with the Combination Company Intends ...
2023-11-22 14:22:43 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips In this market cycle that we are experiencing, new opportunities arise to take advantage of over the next few years. There is no better way to take advantage of these opportunities than through...
News, Short Squeeze, Breakout and More Instantly...
GenFleet’s IND in China was cleared in June 2024; this is the first discovery program from the collaboration Verastem announced in 2023 to advance into human clinical trials Verastem plans to initiate development studies outside of China after evaluating initial dose escalation dat...
Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced that in connection with the 2024 Russell U.S. Indexes annual reconstitution, the company will be added to the Russell 3000 ® and Russell Microcap ...
2024-06-12 09:44:18 ET USA News Group Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 12, 2024 – USA News Group – After looking at public health records for 3.8 million patients with invasive spreading cancer, researchers recently discovere...